CoChat

Body Composition and Survival in Locally Advanced Rectal Cancer Patients Treated with Neoadjuvant Radiochemotherapy

Kolenda, Piotr, Mardas, Marcin, Radomyski, Piotr, Trojanowski, Maciej, Litwiniuk, Maria, Warchoł, Wojciech, Stelmach-Mardas, Marta · 2025 · Nutrients
Cited by 5

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background: Nutritional status is a recognized determinant of treatment tolerance and clinical outcomes in oncology. This study aimed to assess body composition using computed tomography (CT) and to evaluate its association with progression-free survival (PFS) and overall survival (OS) in patients with locally advanced rectal cancer (LARC) undergoing curative multimodal therapy. Methods: A total of 216 patients with LARC who underwent neoadjuvant chemoradiotherapy (CRT) were retrospectively assessed. Two radiochemotherapy protocols were used: long-course chemoradiotherapy (lcCRT) (radiation therapy administered daily at doses of 1.8 or 2.0 Gy, for a total dose of 50.4–55.8 Gy) with concurrent chemotherapy: either 5-FU with leucovorin or capecitabine and total neoadjuvant chemoradiotherapy (tnCRT)—short-course radiotherapy (5 × 5 Gy) followed by sequential chemotherapy with CAPOX or FOLFOX. Surgery was performed 6.5 weeks after completing CRT. Radiotherapy was delivered using linear accelerators based on the Intensity-Modulated Radiation Therapy technique. CT scans were used to assess nutritional status. Survival analyses were performed. Data on food consumption frequency were collected using the Dietary Habits and Nutrition Beliefs Questionnaire (KomPAN®). Non-Healthy-Diet-Index-14 (nHDI-14) was calculated. Results: Median observation time was 58 months (range 4–118 months). VATI level and OS (HR: 0.4618 95% CI: 0.2194–0.9719, p = 0.0419), as well as SATI and OS (HR: 0.4707 95% CI: 0.2286–0.9693, p = 0.0409) were significantly associated. This association was not significant for PFS (VATI: HR: 0.7084 95% CI: 0.4055–1.2376, p = 0.2259; SATI: HR: 0.6864 95% CI: 0.3932–1.1981, p = 0.1855). SMI and PMI values were not significantly related either PFS (SMI-HR: 0.6728, 95% CI: 0.4031–1.1231, p = 0.1295; PMI-HR: 0.7385, 95% CI: 0.4628–1.1785, p = 0.2036) or OS (SMI-HR: 0.9128, 95% CI: 0.4703–1.7720, p = 0.7876; PMI-HR: 0.6592 95% CI: 0.3684–1.1794, p = 0.1603). No significant association was found between sarcopenia development and PFS (HR: 1.2733 CI: 0.7589–2.1363; p = 0.3602) or OS (HR: 1.1207; CI: 0.5681–2.2107; p = 0.7424). Significant differences between men and women in alcohol intake and nHDI-14 were observed. Conclusions: Low visceral and subcutaneous adipose tissue index were significantly associated with worse OS in patients with LARC undergoing multimodal treatment. The nHDI-14 was negatively correlated with the duration of observation and patients’ age.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu17203309

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 36

  1. Sayer, 2019, Sarcopenia, Lancet, 393, 2636, 10.1016/S0140-6736(19)31138-9 · DOI · Paper page
  2. Hopkins, 2019, The Impact of Muscle and Adipose Tissue on Long-term Survival in Patients With Stage I to III Colorectal Cancer, Dis. Colon Rectum, 62, 549, 10.1097/DCR.0000000000001352 · DOI
  3. Feliciano, 2017, Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study, JAMA Oncol., 3, e172319, 10.1001/jamaoncol.2017.2319 · DOI · Paper page
  4. Choi, 2018, Sarcopenia is negatively associated with long-term outcomes in locally advanced rectal cancer, J. Cachexia Sarcopenia Muscle, 9, 53, 10.1002/jcsm.12234 · DOI · Paper page
  5. Yamano, 2020, Influence of chemoradiotherapy on nutritional status in locally advanced rectal cancer: Prospective multicenter study, Nutrition, 77, 110807, 10.1016/j.nut.2020.110807 · DOI
  6. Bai, 2023, A clinical study on the nutritional status of patients with locally advanced rectal cancer during chemo-radiotherapy, Ann. Ital. Chir., 94, 73
  7. Takeda, Y., Akiyoshi, T., Matsueda, K., Fukuoka, H., Ogura, A., Miki, H., Hiyoshi, Y., Nagasaki, T., Konishi, T., and Fujimoto, Y. (2018). Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy. PLoS ONE, 13. · DOI
  8. Bahadoer, 2021, Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial, Lancet Oncol., 22, 29, 10.1016/S1470-2045(20)30555-6 · DOI · Paper page
  9. Boutin, 2015, Sarcopenia: Current Concepts and Imaging Implications, Am. J. Roentgenol., 205, W255, 10.2214/AJR.15.14635 · DOI · Paper page
  10. Prado, 2008, Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study, Lancet Oncol., 9, 629, 10.1016/S1470-2045(08)70153-0 · DOI · Paper page
  11. Nishikawa, 2016, Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria, Hepatol. Res., 46, 951, 10.1111/hepr.12774 · DOI · Paper page
  12. Ghalehtaki, 2024, Optimal Sequence for Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: An Evidence-Based Review, Cancer Med., 13, e70291, 10.1002/cam4.70291 · doi:10.1002/cam4.70291
  13. Mardas, 2015, Dietary habits changes and quality of life in patients undergoing chemotherapy for epithelial ovarian cancer, Support Care Cancer, 23, 1015
  14. Li, 2025, Visceral adipose tissue predicts perioperative complications of total neoadjuvant therapy for locally advanced rectal cancer: A multicenter real-world study, Surgery, 185, 109548, 10.1016/j.surg.2025.109548 · doi:10.1016/j.surg.2025.109548
  15. Huang, W., Feng, Z., Ma, M., Song, F., Zeng, S., Shao, F., Yu, X., Rong, P., and Chen, J. (2024). Different impacts of adipose tissue dynamics on prognosis in patients with resectable locally advanced rectal cancer treated with and without neoadjuvant treatment. Front. Oncol., 14. · DOI
  16. Bocca, 2022, Visceral-to-subcutaneous fat ratio exhibits strongest association with early post-operative outcomes in patients undergoing surgery for advanced rectal cancer, Int. J. Color. Dis., 37, 1893, 10.1007/s00384-022-04221-8 · DOI
  17. Clark, 2013, Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation, J. Am. Coll. Surg., 216, 1070, 10.1016/j.jamcollsurg.2013.01.007 · DOI
  18. Bagdassarjan, 2019, CT-Quantified Adipose Tissue Distribution: Risk or Protective Factor for Complications after Rectal Cancer Surgery?, Obes. Facts, 12, 259, 10.1159/000499320 · DOI
  19. Pacquelet, 2022, Abdominal adipose tissue quantification and distribution with CT: Prognostic value for surgical and oncological outcome in patients with rectal cancer, Eur. Radiol., 32, 6258, 10.1007/s00330-022-08697-4 · DOI
  20. Luo, 2025, The Ratio of Visceral to Subcutaneous Adipose Tissue Is Associated With Postoperative Anastomotic Leakage in Patients With Rectal Cancer With Gender Differences in Opposite Direction, Cancer Med., 14, e70933, 10.1002/cam4.70933 · DOI
  21. Liu, 2023, Associations of muscle and adipose tissue parameters with long-term outcomes in middle and low rectal cancer: A retrospective cohort study, Cancer Imaging, 23, 5, 10.1186/s40644-022-00514-x · DOI
  22. Temel, 2025, Investigation of the relationship between mesorectal adipose tissue volume measured by computed tomography and histopathological prognostic features in patients with rectal cancer, Eur. J. Radiol., 190, 112261, 10.1016/j.ejrad.2025.112261 · DOI
  23. Salandini, 2020, Changes in body composition during neoadjuvant therapy can affect prognosis in rectal cancer patients: An exploratory study, Curr. Probl. Cancer, 44, 100510, 10.1016/j.currproblcancer.2019.100510 · DOI · Paper page
  24. Levolger, 2018, Muscle wasting and survival following pre-operative chemoradiotherapy for locally advanced rectal carcinoma, Clin. Nutr., 37, 1728, 10.1016/j.clnu.2017.06.028 · DOI
  25. Wei, 2025, Artificial intelligence measured 3D lumbosacral body composition and clinical outcomes in rectal cancer patients, ANZ J. Surg., 95, 163, 10.1111/ans.19312 · DOI
  26. Mols, 2025, High consumption of ultra-processed food and risk of colorectal cancer: The Norwegian Women and Cancer cohort study, Br. J. Nutr., 16, 1, 10.1017/S0007114525105114 · DOI
  27. Huybrechts, 2022, Food processing groups and colorectal cancer risk in Morocco: Evidence from a nationally representative case-control study, Eur. J. Nutr., 61, 2507, 10.1007/s00394-022-02820-3 · DOI
  28. Deoula, 2020, Consumption of meat, traditional and modern processed meat and colorectal cancer risk among the Moroccan population: A large-scale case-control study, Int. J. Cancer, 146, 1333, 10.1002/ijc.32689 · DOI
  29. Hullings, 2020, Whole grain and dietary fiber intake and risk of colorectal cancer in the NIH-AARP Diet and Health Study cohort, Am. J. Clin. Nutr., 112, 603, 10.1093/ajcn/nqaa161 · DOI
  30. Jones, 2018, Does adherence to the World Cancer Research Fund/American Institute of Cancer Research cancer prevention guidelines reduce risk of colorectal cancer in the UK Women’s Cohort Study?, Br. J. Nutr., 119, 340, 10.1017/S0007114517003622 · DOI
  31. Korczak, J., Mardas, M., Litwiniuk, M., Bogdański, P., and Stelmach-Mardas, M. (2023). Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia. Nutrients, 15. · DOI
  32. Mardas, 2025, Changes in nutritional status in hepatocellular carcinoma patients treated with sorafenib, Support Care Cancer, 33, 901
  33. Ragusa, 2025, ODIASP: An Open-Source Software for Automated SMI Determination-Application to an Inpatient Population, J. Cachexia Sarcopenia Muscle, 16, e70023, 10.1002/jcsm.70023 · DOI
  34. Cao, 2023, Can AI-based body composition assessment outperform body surface area in predicting dose-limiting toxicities for colonic cancer patients on chemotherapy?, J. Cancer Res. Clin. Oncol., 149, 13915, 10.1007/s00432-023-05227-7 · DOI
  35. Soria-Utrilla, V., Sánchez-Torralvo, F.J., Palmas-Candia, F.X., Fernández-Jiménez, R., Mucarzel-Suarez-Arana, F., Guirado-Peláez, P., Olveira, G., García-Almeida, J.M., and Burgos-Peláez, R. (2024). AI-Assisted Body Composition Assessment Using CT Imaging in Colorectal Cancer Patients: Predictive Capacity for Sarcopenia and Malnutrition Diagnosis. Nutrients, 16. · DOI
  36. Urooj, 2025, Implementation of Fully Automated AI-Integrated System for Body Composition Assessment on Computed Tomography for Opportunistic Sarcopenia Screening: Multicenter Prospective Study, JMIR Form. Res., 9, e69940, 10.2196/69940 · DOI

Metadata

Authors
Kolenda, P., Mardas, M., Radomyski, P., Trojanowski, M., Litwiniuk, M., Warchoł, W., & Stelmach-Mardas, M.
Affiliations
  • Greater Poland Cancer Centre, Department of Oncology and Immuno-Oncology, Garbary Str. 15, 61-866 Poznan, Poland
  • Poznan University of Medical Sciences, Institute of Oncology, Department of Gynaecological Oncology, Szamarzewskiego Str. 82/84, 60-569 Poznan, Poland
  • Poznan University of Medical Sciences, Electroradiology Department, Garbary Str. 15, 61-866 Poznan, Poland
  • Greater Poland Cancer Centre, Greater Poland Cancer Registry, Garbary Str 15, 61-866 Poznan, Poland
  • Poznan University of Medical Sciences, Department of Optometry, Rokietnicka Str. 5D, 60-806 Poznan, Poland
  • Poznan University of Medical Sciences, Department of Obesity Treatment, Metabolic Diseases and Clinical Dietetics, Przybyszewskiego Str. 49, 60-355 Poznan, Poland
Venue
Nutrients
Publisher
MDPI AG
Published
2025-10-21
Volume
17
Issue
20
Pages
3309
ISSN
2072-6643
Cited by
5
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.